Atara ($ATRA) EBVALLO Approval and Manufacturing Issues Case

Investors can submit applications for the lead plaintiff role.

C.D. California

Court

2:26-cv-03083

Case number

05/20/2024

Class period Start

01/09/2026

Class period End

05/22/2026

Lead Plaintiff motion deadline

$ATRA investors filed a claim against Atara for allegedly overstating EBVALLO’s approval prospects while concealing manufacturing problems and flaws in the ALLELE study.
After Atara disclosed an FDA rejection tied to a third-party manufacturing facility and later revealed a clinical hold and study-related concerns, $ATRA fell 55.3% on January 12, 2026.
$ATRA investors can join this case to be notified about potential recovery.
Case Details:

Between May 20, 2024 and January 9, 2026, Atara told investors its EBVALLO biologics application was supported by strong clinical data and was progressing toward FDA approval. Executives emphasized the ALLELE study’s response rates, the FDA’s acceptance and priority review of the filing, and the company’s work with Pierre Fabre to prepare for a potential U.S. launch.

However, during this period, investors allege Atara faced serious undisclosed obstacles to approval. Atara allegedly failed to disclose that manufacturing problems at a third-party facility made FDA approval unlikely.That weaknesses in the ALLELE study undermined the evidence supporting EBVALLO, and that these issues created added regulatory risk and threatened ongoing clinical programs.

Then, on January 16, 2025, the company revealed it had received an FDA Complete Response Letter tied to inspection observations at a third-party manufacturing facility for EBVALLO. $ATRA fell 40.5%, closing at $7.83. 

Additional revelations followed on January 21, 2025, including that the FDA had placed Atara’s active drug applications on clinical hold because manufacturing compliance issues had not been adequately addressed. 

By January 12, 2026, shares had dropped to $5.88, representing a total decline of 55.3% over the correction period.

Based on these events, $ATRA investors filed a claim against Atara, alleging the company:
It overstated EBVALLO’s path to FDA approval.
It hid manufacturing and study problems that undermined the filing.
It caused investors losses when those problems came to light.
Investors argue Atara misled the market about EBVALLO’s regulatory readiness and supporting evidence, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management,

Other

Security Type

Stocks

Trade Direction

Long

Shock Event Date

01/16/2026

Filing date

03/23/2026

Lead Plaintiff Deadline

05/22/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.